New research may improve the diagnosis and treatment of antiphospholipid antibody syndrome
Antiphospholipid antibody syndrome (APS) is an autoimmune disorder that occurs when the immune system mistakenly attacks normal proteins in the blood. An antibody is a type of protein that normally protects the body against infections. But in APS, the body produces antibodies directed against phospholipids -- a class of lipids found in cell membranes. These antiphospholipid antibodies dysregulate cellular activities, provoke blood clots (thrombosis), and cause pregnancy complications.
Recently, a team of researchers at the University Hospital of Geneva and Faculty of Medicine and the University of Geneva have identified where antiphospholipid antibodies attach themselves, a finding that would lead to new diagnostic tools and targeted treatments for APS. The researchers have published their findings in the journal 'Haematologica', and Philippe de Moerloose of the University Hospital of Geneva and Faculty of Medicine is the first author.
Previous studies have revealed that the main antigenic determinant for antiphospholipid antibodies is the beta-2-glycoprotein 1 (β2GP1). Anti-β2GP1 antibodies bind to the surfaces of certain cells, such as endothelial cells and monocytes, to increase the production of pro-inflammatory and pro-thrombotic factors. But the exact location where anti-β2GP1 antibodies bind is unclear. The goal of the new study is to find the answer.
Moerloose and colleagues identified a sequence in the domain I of β2GP1 that triggers the proliferation of CD4+ T cells from patients with APS. By comparing this sequence with the previously reported antiphospholipid antibodies-binding epitope, the researchers found an indeterminate motif in β2GP1 that interacts with antiphospholipid antibodies. Further experiments confirmed that peptides and domains of β2GP1 that contain this motif pattern could interact with antiphospholipid antibodies in vitro and reduce their ability to activate monocytes.
Currently, there is no cure for APS, and treatments such as anticoagulant medication can cause side effects. Identification of antiphospholipid antibodies-interacting motifs may contribute to the development of better diagnostic tools and potential β2GP1-based therapies for APS.
In addition, CusAb offers β2GP1 recombinant protein and β2GP1 antibody for researchers.